There are 2789 resources available
914P - Impact of induction chemotherapy (ICT) in borderline resectable or unresectable locally advanced oral squamous cell carcinoma (OSCC)
Presenter: Divya Kukreja
Session: ePoster Display
924P - HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany
Presenter: Harald Müller-Huesmann
Session: ePoster Display
926TiP - Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
Presenter: Grzegorz Obara
Session: ePoster Display
986P - Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice
Presenter: Toshihide Nishibata
Session: ePoster Display
987P - A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
Presenter: toshifumi obonai
Session: ePoster Display
988P - Ocular complications of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: A multi-center prospective observational cohort study
Presenter: Kevin Sheng-Kai Ma
Session: ePoster Display
989P - Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)
Presenter: Sofia Genta
Session: ePoster Display
990P - Endocrine immune-related adverse events (irAEs) of combined immunotherapy in solid tumors: Systematic review and meta-analysis
Presenter: Nikolaos Tsoukalas
Session: ePoster Display
991P - Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
Presenter: Thierry André
Session: ePoster Display